Therapeutic Or Pharmaceutical Composition Patents (Class 977/915)
-
Patent number: 8574315Abstract: The present invention relates to structures that contain one or more fiber and/or nanofiber structures where such structures can be formed on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In one embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In another embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.) where such fibers and/or structures are designed to sequester, carry and/or encapsulate one or more substances.Type: GrantFiled: May 9, 2007Date of Patent: November 5, 2013Assignee: The University of AkronInventors: Darrell Reneker, Tao Han, Daniel Smith, Camden Ertley, Joseph W. Reneker
-
Publication number: 20130281515Abstract: A cationic bis-urea compound is disclosed of formula (1): wherein: each m is independently an integer of 0 to 4, each k is independently 0 or 1, each Z? is a monovalent radical independently selected from the group consisting of hydroxyl (*—OH), carboxyl (*—COOH), cyano (*—CN), nitro (*—NO2), sulfonate (*—SO3?), trifluoromethyl (*—CF3), halides, amine groups, ketone groups, alkyl groups comprising 1 to 6 carbons, alkoxy groups comprising 1 to 6 carbons, thioether groups comprising 1 to 6 carbons, and combinations thereof, each L? is independently a divalent alkylene group comprising 1 to 6 carbons, wherein a *-[-L?-]k- is a single bond when k is 0, each Y? is independently a monovalent non-polymeric radical comprising a positive charged amine, and each X? is independently a negative charged counterion.Type: ApplicationFiled: April 18, 2012Publication date: October 24, 2013Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Daniel Joseph Coady, Amanda Catherine Engler, Kazuki Fukushima, James Lupton Hedrick, Shaoqiong Liu, Hareem Tariq Maune, Alshakim Nelson, Jed Walter Pitera, Yi Yan Yang
-
Patent number: 8562966Abstract: Poly(beta-amino esters) are end-modified to form materials useful in the medical as well as non-medical field. An amine-terminated poly(beta-amino ester) is reacted with an electrophile, or an acrylate-terminated poly(beta-amino ester) is reacted with a nucleophile. The inventive end-modified polymers may be used in any field where polymers have been found useful including the drug delivery arts. The end-modified polymers are particularly useful in delivery nucleic acids such as DNA or RNA. The invention also provides compositions including the inventive end-modified polymers, methods of preparing the inventive polymers, and method of using the inventive polymers.Type: GrantFiled: December 6, 2011Date of Patent: October 22, 2013Assignee: Massachusetts Institute of TechnologyInventors: Gregory T. Zugates, Andreas Zumbuehl, Robert S. Langer, Daniel Griffith Anderson
-
Publication number: 20130259905Abstract: A composition capable of inducing endoplasmic reticulum stress including nanogold particles and a solvent is disclosed. After a chronic myelogenous leukemia patient intakes the composition capable of inducing endoplasmic reticulum stress, the endoplasmic reticulum stress of the chronic myelogenous leukemia cells is induced to cause apoptosis and cell death, so as to alleviate and control chronic myelogenous leukemia.Type: ApplicationFiled: July 5, 2012Publication date: October 3, 2013Applicant: GOLD NANOTECH INC.Inventors: Chen Han-Min, Tan Shan-Wen
-
Publication number: 20130236548Abstract: A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-based particles to a subject in need, wherein the Fe-based particles have core-shell structures. Herein, each Fe-based particle of the present invention comprises: an Fe elemental core with zero valent irons; and a covering layer formed on partial or whole surface of the Fe elemental core, wherein a material of the covering layer is a metal, a metal doped with dopants, a metal alloy, a polymer, carbon, a metal oxide or a nonmetal oxide, and the shape of the Fe-based particles is a rod, a sphere, a cubic or a dumbbell, with the proviso that the metal is not Au.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Dar-Bin SHIEH, Li-Xing YANG, Ya-Na WU
-
Publication number: 20130236507Abstract: A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-containing alloy particles to a subject in need, wherein a material of each Fe-containing alloy particle is an alloy comprising a first metal of Fe and a second metal.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Dar-Bin SHIEH, Li-Xing YANG, Ya-Na WU
-
Publication number: 20130230463Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.Type: ApplicationFiled: March 2, 2012Publication date: September 5, 2013Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan HAY, Daniel Eugene MEYER, Brian Christopher BALES, Michael Todd LUTTRELL
-
Publication number: 20130216588Abstract: An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein the insulin-gold nanocluster emits red fluorescence at maximized wavelength of 670 nm.Type: ApplicationFiled: February 17, 2012Publication date: August 22, 2013Inventors: Pi-Tai CHOU, Chien-Liang Liu, Yun-Chen Chien
-
Patent number: 8513446Abstract: The invention relates to stable crystal modifications of (R,S)-, (R)- and (S)-DOPC, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.Type: GrantFiled: May 13, 2009Date of Patent: August 20, 2013Assignee: Merck Patent GmbHInventors: Michael Platscher, Alfred Hedinger
-
Patent number: 8507778Abstract: Self-assembling multimeric physical models of closed polyhedral structures made of structurally symmetric units, and which mimic the structure and self-assembly characteristics of naturally occurring systems such as viral capsids, are provided. Also provided are methods of creating structurally symmetric units, kits for forming self-assembling physical models of polyhedral structures, and methods of forming the same.Type: GrantFiled: March 13, 2008Date of Patent: August 13, 2013Inventor: Arthur J. Olson
-
Patent number: 8501239Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: GrantFiled: December 18, 2012Date of Patent: August 6, 2013Assignee: University of Kentucky Research FoundationInventor: Patrick Sullivan
-
Patent number: 8496945Abstract: Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.Type: GrantFiled: May 17, 2011Date of Patent: July 30, 2013Assignee: Washington UniversityInventors: Paul Schlesinger, Neelesh Soman, Gregory Lanza, Samuel A. Wickline
-
Patent number: 8454984Abstract: Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional acrylic monomer, about 5 weight % to about 40 weight % of an adhesion-promoting acrylic or vinyl monomer, and about 0.1 weight % to about 15 weight % of a metal salt; and exposing the mixture to a radiation source to cure at least a portion of the mixture, thereby forming an antimicrobial resin.Type: GrantFiled: September 11, 2012Date of Patent: June 4, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Vadim V. Krongauz, Dustin C. Cawthon, Michael Tung-Kiung Ling
-
Publication number: 20130136775Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.Type: ApplicationFiled: November 30, 2011Publication date: May 30, 2013Inventors: Andreas Voigt, Jörg Kriwanek, Scott Hampton, Andreas Reiff, Sonja Ludwig
-
Patent number: 8449896Abstract: It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X (FXa), and is useful as an agent for preventing and/or treating thrombosis, wherein the pharmaceutical composition exhibits favorable dissolution properties. The present invention relates to a solid pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, wherein the content of the compound represented by formula (I) is 0.5% by weight or more and less than 15% by weight with respect to the total weight of the pharmaceutical composition.Type: GrantFiled: December 16, 2011Date of Patent: May 28, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Makoto Kamada, Motonori Kidokoro, Gaku Sekiguchi
-
Patent number: 8445025Abstract: Disclosed are the nanoparticle and the method for the same, and the preparing method includes steps of mixing polyethylenimine (PEI) with the poly(acrylic acid)-bound iron oxide (PAAIO) to form a PEI-PAAIO polyelectrolyte complex (PEC) and mixing the PEI-PAAIO PEC with genetic material such as plasmid DNA to form the PEI-PAAIO/pDNA magnetic nanoparticle. The PEI-PAAIO/pDNA magnetoplex is highly water dispersible and suitable for long term storage, shows superparamagnetism, low cytotoxicity, high stability and nice transfection efficiency, and thus the PEI-PAAIO PEC can replace PEI as a non-viral gene vector.Type: GrantFiled: March 29, 2011Date of Patent: May 21, 2013Assignee: Kaohsiung Medical UniversityInventors: Li-Fang Wang, Shuo-Li Sun, Yu-Lun Lo
-
Publication number: 20130122063Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: ApplicationFiled: December 18, 2012Publication date: May 16, 2013Applicant: University of Kentucky Research FoundationInventor: University of Kentucky Research Foundation
-
Patent number: 8440893Abstract: When C60 was added to synovial fibroblasts, infiltrating lymphocytes, and macrophages, and the inflammatory cytokine production level was measured, the inflammatory cytokine production level was significantly suppressed in all cells. Furthermore, when C60 was added to osteoclast precursor cells and cultured in the presence of osteoclast differentiation-inducing factors, a certain concentration or more of C60 suppressed their differentiation into osteoclasts. Observation of the effect of C60 addition on bone resorption showed that C60 suppressed bone resorption by osteoclasts. In addition, the use of arthritis model animals confirmed in vivo that C60 suppressed inflammatory symptoms, as well as bone resorption and bone destruction by osteoclasts. C60 is effective for treating arthritic diseases such as rheumatoid arthritis through its effects of suppressing osteoclast differentiation, bone resorption, and inflammatory cytokines.Type: GrantFiled: October 18, 2007Date of Patent: May 14, 2013Assignees: St. Marianna University School of Medicine, Mitsubishi CorporaionInventor: Kazuo Yudoh
-
Publication number: 20130116261Abstract: The present invention relates to nanoparticles for the encapsulation of compounds, the obtaining and uses thereof. The nanoparticles comprise a zein matrix and a basic amino acid. Said nanoparticles can encapsulate a water-soluble or fat-soluble biologically active compound. It is applicable in the food, pharmaceutical and cosmetic sectors and in the nanotechnology sector.Type: ApplicationFiled: July 15, 2011Publication date: May 9, 2013Applicants: UNIVERSIDAD DE NAVARRA, CENTRO NACIONAL DE TECNOLOGÍA Y SEGURIDAD ALIMENTARIA, LABORATORIO DEL EBROInventors: Maite Agüeros Bazo, Irene Esparza Catalán, Carolina González Ferrero, Carlos Javier González Navarro, Juan Manuel Irache Garreta, Ana Romo Hualde
-
Publication number: 20130115246Abstract: The invention relates to reduced dose oral pharmaceutical composition of fenofibrate which exhibits substantial bioequivalence to Antara® Capsules under fasting condition and also capable of reducing the food effect on bioavailability of fenofibrate. Provided is a pharmaceutical composition comprising about 90 mg of fenofibrate particles having a D90 particle size of less than about 600 nm and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a solid dosage form suitable for oral administration and is substantially free of food effect such that when administered orally to a human provides an AUC0-t value for fenofibric acid in the blood plasma of the human under a fed state which is higher than the AUC0-t value under a fasted state by up to 12%, wherein t is 96 hours from the administration of the pharmaceutical composition.Type: ApplicationFiled: January 13, 2012Publication date: May 9, 2013Applicant: Lupin Atlantis Holdings, S.A.Inventors: Venkat Reddy KALLEM, Raghu Rami Reddy KASU, Subhasis DAS, Vijaya Kumar THOMMANDRU, Ninad DESHPANDAY
-
Publication number: 20130108667Abstract: A method, apparatus and system that employs particles, e.g., nanoparticles, and an electric or electro-magnetic field, to cause electroporation in target cells at reduced fields. Electroporation may be irreversible, leading to targeted cell death, or reversible, allowing species to be introduced into the target cell. The method introduces a particle to a position adjacent to the cell membrane of a target cell and exposes the target cell to a transient electromagnetic field for a time interval to cause targeted electroporation. A smaller electric field is applied, thereby surmounting similar methods. The particle enhances the effect of the electric field in its immediate vicinity, so reducing the field strength needed to achieve electroporation and thereby reducing the risk of damage to cells through high field exposure. Electroporation can be targeted to a subset of target cells by targeting the particles to surface markers on the target cell membrane.Type: ApplicationFiled: October 27, 2011Publication date: May 2, 2013Inventors: Soiwisa Soikum, Lars Thomsen, John Robert Dodgson
-
Patent number: 8431143Abstract: A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required.Type: GrantFiled: September 24, 2010Date of Patent: April 30, 2013Assignee: Toto Ltd.Inventors: Shuji Sonezaki, Koki Kanehira, Yumi Ogami, Toshiaki Banzai, Yoshinobu Kubota
-
Publication number: 20130102591Abstract: The invention provides compositions and methods for prevention, treatment, or management of pulmonary hypertension using piperidine, pyrrolidine, or azepane derivatives comprising one to four nitric oxide (NO) donor groups and a reactive oxygen species (ROS) degradation catalyst. The invention further provides a water dispersible powder comprising nanoparticles comprising said derivatives, as well as pharmaceutical compositions thereof and methods of use.Type: ApplicationFiled: January 26, 2011Publication date: April 25, 2013Inventors: Andrew Lurie Salzman, Shlomo Magdassi, Katrin Margulis-Goshen
-
Publication number: 20130095042Abstract: Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-KB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions.Type: ApplicationFiled: November 20, 2012Publication date: April 18, 2013Applicants: Seoul National University Industry Foundation, EMORY UNIVERSITYInventors: Emory University, Seoul National University Industry Foundation
-
Publication number: 20130095184Abstract: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.Type: ApplicationFiled: April 25, 2008Publication date: April 18, 2013Applicant: NUCRYST PHARMACEUTICALS CORP.Inventors: Jeffrey B. Lyczak, Katherine Thompson, Katherine Turner, Paul Schechter
-
Publication number: 20130096485Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors. In embodiments, the methods comprise the use of high aspect ratio nanoparticles with or without modified surface chemistry.Type: ApplicationFiled: October 30, 2009Publication date: April 18, 2013Inventors: Rafael V. DAVALOS, Marissa N. RYLANDER, Christopher B. ARENA
-
Publication number: 20130095198Abstract: A process for the production of nanocrystals or amorphous nanoparticles of actives (nanomaterials), especially from the peels of grapes. A dispersion of a micrometer-sized material in a solution of surfactant or a steric stabilizer is first provided. The macrosuspension is then stirred for at least 1 minute at a rotational speed above 500 rpm using a rotor-stator mixer. The stirred mixture is passed through a jet stream or piston-gas type high pressure homogenizer. The nanomaterials produced can be incorporated into formulations for use as nutraceutical, nutritional supplement, or as supportive treatment in medical therapy. The active can be derived from the peels of grapes.Type: ApplicationFiled: October 11, 2012Publication date: April 18, 2013Applicant: PHARMASOL GMBHInventor: PharmaSol GmbH
-
Publication number: 20130090237Abstract: In one embodiment, a method includes making a pteredin phenyl pentanedioic (3P) formulation by providing an aqueous solution including one of more 3P molecules neutralized with one or more of an alkali, an alkali earth metal hydroxide, or an alkali carbonate; adding to the aqueous solution one of a surfactant, dispersant, or additive with the guest molecules; and non-covalently crosslinking the 3P formulation by exposing the 3P formulation to an excess solution of multivalent cation salt.Type: ApplicationFiled: October 11, 2011Publication date: April 11, 2013Inventor: Sanat Mohanty
-
Publication number: 20130084339Abstract: The present invention relates to a composition comprising a nanocomposite or nanostructured powder which comprises an aluminium silicate and, distributed on the surface thereof, silver nanoparticles with sizes of less than 50 nm, to its use as a bactericide and to a process for obtaining said composition.Type: ApplicationFiled: April 15, 2011Publication date: April 4, 2013Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASInventors: Maria Belen Cabal, Jose S. Moya Corral
-
Publication number: 20130079382Abstract: Compositions and methods for down modulating target gene expression with RNA interference, as well as methods for administering said compositions are disclosed. The method comprises administering a first strand to a cell, incubating the cell for a time period suitable for uptake of the first oligo prior to administering a second strand, wherein the first strand and said second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA.Type: ApplicationFiled: October 12, 2010Publication date: March 28, 2013Inventor: Larry J. Smith
-
Publication number: 20130078288Abstract: A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents.Type: ApplicationFiled: November 20, 2012Publication date: March 28, 2013Inventor: Chun Ho Yu
-
Patent number: 8404281Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.Type: GrantFiled: June 8, 2010Date of Patent: March 26, 2013Assignee: Avant Garde Therapeutics & Technologies LLCInventors: Leo Rubin, Shaker Mousa
-
Publication number: 20130071472Abstract: The present invention relates to a method for preparing a capsule nanoparticle used in encapsulating hydrophobic medicines, comprising the following steps: (A) providing a biocompatible polymer and an organic solution containing a hydrophobic medicine; (B) stirring the organic solution at 3-10° C., and titrating with an alcohol solution, so as to make the biocompatible polymer encapsulate hydrophobic medicine to form a capsule nanoparticle; (C) ultrasonic vibrating the capsule nanoparticle at 3-10° C.; (D) filtering the capsule nanoparticle to an average size controllable in the range of 60-450 nm; and (E) lyophilizing the encapsulated particles.Type: ApplicationFiled: September 21, 2012Publication date: March 21, 2013Inventor: Dar-Bin SHIEH
-
Publication number: 20130065227Abstract: This disclosure describes methods of stimulating macropinocytosis in cancer cells.Type: ApplicationFiled: March 4, 2011Publication date: March 14, 2013Inventors: Paula J. Bates, Elsa Merit Reyes-Reyes
-
Publication number: 20130065849Abstract: The invention relates to compounds of formula (I) wherein the groups A and B represent independently from each other —CH?CH—, or —C?C—, the terms t, u, v, w represent, independently from each other, values ranging from 0 to 9, the groups Y1 and Y2 can represent independently from each other an alkyl group (linear, branched or substituted) carrying from 1 to 9 carbon atoms, the groups Z1, Z2, Z3, and Z4 can represent independently from each other a chemically reactive group W, such as OH, NH2, SH, the groups Z5 and Z6 represent independently from each other a hydrogen atom, silica nanoparticles functionalized by these compounds, and their use as drugs.Type: ApplicationFiled: December 7, 2010Publication date: March 14, 2013Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, UNIVERSITE DE RENNES 1Inventors: David Brevet, Laurence Raehm, Mireille Blanchard-Desce, Olivier Mongin, Magali Gary-Bobo-Sable-Teychene, Marcel Garcia, Alain Morere, Jean-Olivier Durand
-
Patent number: 8395037Abstract: Fullerene inhibited the decrease in cell proliferation ability of chondrocytes which is observed when cultured chondrocytes are treated with a cartilage degenerating factor (IL-1? or H2O2). Fullerene inhibited production of cartilage matrix-degrading enzymes (matrix metalloprotease (MMP)-1, 3 and 13) which is induced in cultured chondrocytes by cartilage degenerating factors. Fullerene restored the decrease in cartilage matrix (proteoglycan) synthesizing ability which is observed in treating cultured chondrocytes with cartilage degenerating factors. In an analysis using an osteoarthritis rabbit model, the progress of cartilage degeneration was reduced by administering fullerene. Moreover, the dynamic friction coefficient was decreased by adding fullerene to synovial fluid.Type: GrantFiled: March 23, 2006Date of Patent: March 12, 2013Assignees: Mitsubishi Corporation, St. Marianna University School of MedicineInventor: Kazuo Yudoh
-
Patent number: 8389485Abstract: Methods and compositions for delivering agents (e.g., gene silencing agents) and molecules to cells using yeast cell wall particles are presented herein. Embodiments of the invention are particularly useful for the delivery of nucleic acids (e.g., siRNAs) to cells.Type: GrantFiled: October 29, 2008Date of Patent: March 5, 2013Assignee: University of MassachusettsInventors: Michael P. Czech, Gary R. Ostroff, Myriam Aouadi
-
Publication number: 20130052256Abstract: A system and method for treating human nails afflicted with fungus is now disclosed. The system comprises a hydrogel dressing or pad, a topical agent consisting of a nanosilver treatment agent, a topical carrier in which said treatment agent is dispersed, and an adhesive for securing the hydrogel and treatment agent to a nail in need of such treatment. A kit, method and regimen for treatment of the nail are also disclosed.Type: ApplicationFiled: May 3, 2011Publication date: February 28, 2013Applicant: SPENCO MEDICAL CORPORATIONInventor: Karen Carmody Smith
-
Publication number: 20130052270Abstract: Disclosed herein is the novel use of a gold nanocluser for ameliorating oxidative stress and/or aging of a cultured cell or a subject having an oxidative stress and/or aging condition mediated by a vascular factor. The gold nanocluster has a particle size ranging from about 0.1 to 20 nm, and preferably is dihydrolipoic acid (DHLA) coated gold nanocluster.Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Applicants: CHUNG YUAN CHRISTIAN UNIVERSITY, MACKAY MEMORIAL HOSPITALInventors: Hung-I Yeh, Walter H. Chang, Cheng-An Lin, Hsueh-Hsiao Wang
-
Publication number: 20130052154Abstract: Compositions and methods for the treatment of inflammation are provided.Type: ApplicationFiled: October 5, 2012Publication date: February 28, 2013Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventor: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
-
Publication number: 20130052241Abstract: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.Type: ApplicationFiled: October 24, 2012Publication date: February 28, 2013Applicant: TEIKOKU PHARMA USA, INC.Inventor: TEIKOKU PHARMA USA, INC.
-
Publication number: 20130052255Abstract: A system and method for treating human nails afflicted with fungus, discoloration, or which are unusually thick is now disclosed. The system comprises a hydrogel moist pad or pad, a treatment agent comprising a metallic colloidal suspension having antifungal activity in an aqueous environment, and an adhesive for securing the hydrogel and treatment agent to a nail in need of such treatment. A method and regimen for treatment of the nail is also disclosed.Type: ApplicationFiled: May 3, 2011Publication date: February 28, 2013Applicant: Spenco Medical CorporationInventors: Karen Carmody Smith, Sameer Shums
-
Publication number: 20130045162Abstract: Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent.Type: ApplicationFiled: August 8, 2012Publication date: February 21, 2013Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: James W. Lillard, JR., Shailesh Singh, Rajesh Singh
-
Publication number: 20130045283Abstract: A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with a G-protein coupled to receptor located in the cilia to moderate (enhance or reduce) sensitivity or ability to smell particular odorants. In accordance with an embodiment of the invention, the composition includes one or more odorants.Type: ApplicationFiled: September 21, 2012Publication date: February 21, 2013Applicant: AUBURN UNIVERSITYInventor: Auburn University
-
Publication number: 20130039952Abstract: Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions.Type: ApplicationFiled: December 22, 2010Publication date: February 14, 2013Applicant: LEO PHARMA A/SInventor: Karsten Petersson
-
Publication number: 20130034599Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.Type: ApplicationFiled: January 19, 2011Publication date: February 7, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: C. Shad Thaxton, Chad A. Mirkin, Kaylin M. McMahon, Sushant Tripathy, Raja Kannan Mutharasan, David M. Leander, Andrea Luthi
-
Publication number: 20130034590Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: ApplicationFiled: August 31, 2012Publication date: February 7, 2013Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Patent number: 8367113Abstract: The present invention generally relates to polymers and macromolecules, in particular, to block polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. The moiety, in some embodiments, may have a molecular weight greater than about 1000 Da; for example, the moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may also be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety.Type: GrantFiled: May 15, 2007Date of Patent: February 5, 2013Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Frank X. Gu, Benjamin A. Teply, Robert S. Langer, Omid C. Farokhzad
-
Publication number: 20130028959Abstract: Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse.Type: ApplicationFiled: December 16, 2010Publication date: January 31, 2013Applicants: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Nikita Kiran Malavia, Daniel S. Kohane
-
Patent number: 8362343Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: GrantFiled: February 25, 2011Date of Patent: January 29, 2013Assignee: University of Kentucky Research FoundationInventor: Patrick G. Sullivan